Trio Medicines Ltd. has described β2-adrenoceptor (ADRB2) antagonists reported to be useful for the treatment of cancer, cerebral cavernous malformations, chronic heart failure, chronic obstructive pulmonary disease, hereditary hemorrhagic telangiectasia, migraine and asthma.
